UCB, Eli Lilly-backed ViaNautis raises $25M in Series A to develop genetic nanomedicines

Ayisha Sharma

News Reporter

UK-based biotech ViaNautis Bio has bagged $25 million in a Series A round supported by two Big Pharma companies to advance its nanomedicine technology with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

UCB, Eli Lilly-backed ViaNautis raises $25M in Series A to develop genetic nanomedicines

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: A male contraceptive may prevent 99% of pregnancies. Now it’s up to a small biotech to finish testing it

Gilead partners with AI startup Genesis Therapeutics to make small molecule drugs

GSK to shut down UK antibiotic facility following end of Sandoz contract

Roche's dual GLP-1/GIP results show promising weight loss, but also high rates of vomiting

Roivant unveils its next deal, hoping for TL1A-sized potential from a shelved Bayer lung disease therapy

Adicet follows other cell therapy biotechs in autoimmune pivot

UCB, Eli Lil­ly-backed Via­Nautis rais­es $25M in Se­ries A to de­vel­op ge­net­ic nanomed­i­cines

News Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

UCB, Eli Lilly-backed ViaNautis raises $25M in Series A to develop genetic nanomedicines